menu
    • menu
    [{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Asarina Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Relmada Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Asarina Pharma \/ Relmada Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Pharma \/ Relmada Therapeutics"},{"orgOrder":0,"company":"University of Arizona","sponsor":"National Institute on Aging | Syneos Health | University of Southern California | ADM Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase II","graph3":"University of Arizona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Arizona \/ National Institute on Aging | Syneos Health | University of Southern California | ADM Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"University of Arizona \/ National Institute on Aging | Syneos Health | University of Southern California | ADM Diagnostics"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase I","graph3":"PureTech Health","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ US Department of Defense"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"Seaport Therapeutics","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Seaport Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Seaport Therapeutics \/ General Atlantic","highestDevelopmentStatusID":"7","companyTruncated":"Seaport Therapeutics \/ General Atlantic"},{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Aurevia","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"steroids (not prednisolone derivatives)","graph1":"Neurology","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Asarina Pharma \/ Aurevia","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Pharma \/ Aurevia"},{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Ergomed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"steroids (not prednisolone derivatives)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asarina Pharma \/ Ergomed","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Pharma \/ Ergomed"},{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"steroids (not prednisolone derivatives)","graph1":"Neurology","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asarina Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Allopregnanolone

    Menu

    Allopregnanolone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Asarina Pharma

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Asarina Pharma

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Relmada Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Relmada Acquires Tourette Therapy from Asarina Pharma

                            Details : Relmada acquires Isoallopregnanolone (sepranolone) from Asarina. Sepranolone is a first-in-class GABAA Modulating Steroid Antagonist (GAMSA), being evaluated for Tourette syndrome.

                            Product Name : Isoallopregnanolone

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 06, 2025

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Relmada Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Seaport Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Seaport Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I/ Phase II

                            Sponsor : General Atlantic

                            Deal Size : $225.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Seaport Therapeutics Closes $225M Series B Financing Round

                            Details : Seaport will use the proceeds to advance its clinical-stage pipeline of first and best-in-class medicines, including SPT-300 (glyph allopregnanolone), an oral prodrug of allopregnanolone.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 21, 2024

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : General Atlantic

                            Deal Size : $225.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PureTech Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PureTech Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Heal...

                            Details : LYT-300 (allopregnanolone prodrug) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatme...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 14, 2023

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PureTech Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PureTech Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : US Department of Defense

                            Deal Size : $11.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone...

                            Details : The funding will advance Phase 2 trial of company's therapeutic candidate, LYT-300, an oral prodrug of allopregnanolone, for the treatment of Fragile X-associated Tremor Ataxia Syndrome (FXTAS).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 01, 2023

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : US Department of Defense

                            Deal Size : $11.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PureTech Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PureTech Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of A...

                            Details : LYT-300 (allopregnanolone prodrug) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatme...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 21, 2023

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PureTech Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PureTech Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PureTech to Advance LYT-300 (Oral allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postp...

                            Details : LYT-300 (allopregnanolone) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatment.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 14, 2023

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            PureTech Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PureTech Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Recepto...

                            Details : LYT-300 is a clinical therapeutic candidate that is in development as a potenƟal treatment for a range of neurological and neuropsychological condions. Developed using PureTech's Glyph™ technology plaƞorm, LYT-300 is an oral prodrug of natural allopr...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 19, 2022

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Asarina Pharma

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Asarina Pharma

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Explore the Effect of Sepranolone in Tourette Syndrome

                            Details : Sepranolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tourette Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 28, 2022

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            PureTech Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PureTech Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LY...

                            Details : LYT-300 is an oral prodrug of natural allopregnanolone candidate that is in development as a potential treatment for a range of neurological and neuropsychological conditions. Developed using PureTech's Glyph technology platform.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 14, 2022

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            PureTech Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PureTech Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Tre...

                            Details : LYT-300 (Oral Allopregnanolone), is the first candidate from the GlyphTM technology platform to enter the clinic, making it the third clinical-stage candidate from PureTech’s pipeline.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 07, 2021

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth